[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haydarpasa Numune Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,85,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626255","the-effect-of-local-corticosteroid-injection-in-carpal-tunnel-syndrome-patients-with-type-2-diabetes-100626255",false,"NCT07433257","The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","The Effect of Local Corticosteroid Injection on Electrophysiological and Ultrasonographic Findings in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","Inclusion Criteria\n\n* Carpal Tunnel Syndrome with Type 2 Diabetes Mellitus Group (Group 1):\n\n  * Age between 18 and 75 years\n  * Presence of clinical symptoms compatible with carpal tunnel syndrome (e.g., pain, paresthesia, numbness) for at least 3 months\n  * Patients diagnosed with mild-to-moderate carpal tunnel syndrome based on electrophysiological findings\n  * Diagnosis of type 2 diabetes mellitus\n  * Regulated blood glucose levels, defined as hemoglobin A1c (HbA1c) \\\u003C 7%\n* Idiopathic Carpal Tunnel Syndrome Group (Group 2):\n\n  * Age between 18 and 75 years\n  * Presence of clinical symptoms consistent with carpal tunnel syndrome (e.g., pain, paresthesia, numbness) for at least 3 months\n  * Patients diagnosed with mild-to-moderate carpal tunnel syndrome based on electrophysiological findings\n  * No diagnosis of diabetes mellitus\n\nExclusion Criteria\n\n* Severe carpal tunnel syndrome based on electrophysiological findings\n* Presence of polyneuropathy, cervical radiculopathy, brachial plexopathy, or thoracic outlet syndrome\n* Uncontrolled blood glucose levels in the diabetic group (hemoglobin A1c ≥ 7%)\n* Presence of another systemic disease, other than diabetes mellitus, that may cause carpal tunnel syndrome\n* Presence of a rheumatological disease\n* History of wrist surgery\n* Less than 6 months since a local corticosteroid injection for carpal tunnel syndrome\n* Less than 3 months since completion of a physical therapy program for carpal tunnel syndrome\n* Infection at the intended injection site\n* Presence of malignancy\n* Pregnancy","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","12 Weeks","OBSERVATIONAL","Our study was planned as a prospective observational study aiming to compare the post-intervention recovery process between patients with carpal tunnel syndrome (CTS) and diabetes mellitus and patients with idiopathic carpal tunnel syndrome without diabetes mellitus. Patients who presented to the Physical Medicine and Rehabilitation outpatient clinic with clinical symptoms consistent with carpal tunnel syndrome and who were diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological findings and who received corticosteroid + local anesthetic injection will be included in the study. Data from patients who meet the inclusion and exclusion criteria will be included in the study. Patients' demographic and clinical data will be recorded. Records will be taken before treatment and at 4 and 12 weeks after treatment.",[26,27],"Carpal Tunnel Syndrome (CTS)","Type 2 Diabetes Mellitus (T2DM)","RECRUITING","2026-05-23",{"date":31,"type":32},"2026-05-27","ACTUAL",{"date":34,"type":32},"2026-03-01",{"date":36,"type":21},"2026-07-31",{"name":38,"class":39},"Haydarpasa Numune Training and Research Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100631074","effects-of-2-aticyto-complex-and-d-ribose-on-pain-and-clinical-course-in-patients-with-fibromyalgia-100631074","NCT07495943","Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","Effects of 2-Aticyto Complex and D-Ribose on Pain, Symptoms, and Clinical Course in Patients With Fibromyalgia Syndrome","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria\n* Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year\n* Receiving pregabalin and\u002For duloxetine treatment for at least 3 months\n* Able to live independently in the community\n* Literate and able to record symptoms and responses\n* No cognitive dysfunction that would interfere with answering study questions\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Rheumatologic disease\n* Renal failure\n* Hepatic failure\n* Cardiovascular disease\n* Hypoglycemia or diabetes mellitus\n* Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)\n* Known allergy or hypersensitivity to any active or excipient component of the study syrup\n* Use of any other dietary supplement or nutritional support product during the study period\n* Pregnancy or lactation\n* Active malignancy\n* Active infection\n* Severe psychiatric disease that may interfere with study participation or assessment\n* Refusal to participate or inability to provide informed consent","65 Years",{"count":50,"type":21},200,"INTERVENTIONAL",[53],"NA","This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and\u002For duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.",[56,57],"Fibromyalgia Syndrome","Fibromyalgia",[57,56,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74],"2-Aticyto Complex","D-ribose","FibroThol","Dietary Supplement","Placebo-Controlled","Randomized","Double-Blind","Multicenter Study","Pregabalin","Duloxetine","Pain","Fatique","Sleep Quality","Depression","Anxiety","Quality of Life","NOT_YET_RECRUITING","2026-03-26",{"date":78,"type":32},"2026-04-01",{"date":80,"type":21},"2026-05-04",{"date":82,"type":21},"2027-05-04",{"name":38,"class":39},5,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":92,"targetDuration":4,"studyType":51,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100596275","comparison-of-the-efficacy-of-mesotherapy-and-extracorporeal-shock-wave-therapy-in-patients-with-lateral-epicondylitis-100596275","NCT07043335","Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis","Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis: A Prospective Randomised Controlled Trial","Inclusion Criteria\n\n* Aged between 18 and 65 years\n* Pain and tenderness in the unilateral lateral epicondyle for ≥6 weeks\n* Clinically diagnosed with Lateral Epicondylitis\n* Patients without cognitive deficits who can follow verbal instructions Exclusion Criteria\n* Receiving an interventional injection in the elbow region within the last 3 months\n* Receiving physical therapy in the last 3 months\n* Receiving regular nonsteroidal anti-inflammatory drug (NSAID) treatment in the last 2 weeks\n* History of fracture or surgery in the affected elbow region\n* Chronic inflammatory diseases\n* Acute infection\n* History of malignancy\n* Coagulation disorders\n* Pregnancy\n* Presence of a pacemaker or electronic implants\n* Cervical radiculopathy and entrapment neuropathy\n* Drug allergies\n* BMI \\> 35",{"count":93,"type":21},50,[53],"The goal of this clinical trial is to investigate the efficacy of mesotherapy in patients with lateral epicondylitis and to determine whether it is as effective as extracorporeal shock wave therapy (ESWT).\n\nIs mesotherapy an effective method in patients with lateral epicondylitis?\n\nResearchers will compare Mesotherapy to extracorporeal shock wave therapy (ESWT) in patient with Lateral epicondylitis.\n\nPatients will be randomly assigned to either the Mesotherapy group or the ESWT group using a closed envelope method.\n\n* Group 1 (Mesotherapy group): Patients will receive a total of 5 sessions of mesotherapy, with one session every 7 days.\n* Group 2 (ESWT group): Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.\n\nPatients will be assessed at three time points: before treatment, 30 minutes after the completion of the treatment, and 12 weeks after the completion of the treatment",[97,98],"Lateral Epicondylitis","Tennis Elbow",[100,101,102,103],"elbow pain","mesotherapy","lateral epicondylitis","extracorporeal shock wave therapy","2026-02-16",{"date":106,"type":32},"2026-02-18",{"date":108,"type":32},"2025-07-01",{"date":110,"type":21},"2026-02-20",{"name":38,"class":39},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":18,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":40},"100607070","does-sarcopenia-influence-rotator-cuff-tear-patterns-radiological-insights-from-patients-with-rotator-cuff-syndrome-100607070","NCT07183774","Does Sarcopenia Influence Rotator Cuff Tear Patterns? Radiological Insights From Patients With Rotator Cuff Syndrome","Inclusion Criteria:\n\n1. Patients with rotator cuff syndrome\n2. Aged between 40 and 75 years\n\nExclusion Criteria:\n\n1. History of previous shoulder surgery\n2. Presence of shoulder pathology other than rotator cuff syndrome\n3. History of surgical intervention involving the hip or thigh region\n4. Being wheelchair-bound or bedridden\n5. Presence of an oncologic disease\n6. Diagnosis of any neurological disorder\n7. Presence of cognitive impairment","40 Years",{"count":120,"type":21},104,"Sarcopenia is the loss of muscle mass due to aging, which consequently leads to a decline in muscle function. It is considered an independent risk factor for falls and fractures, disability, postoperative complications, and mortality. Rotator cuff tears are known to be influenced by systemic diseases such as diabetes, hypercholesterolemia, thyroid disorders, and osteoporosis. The aim of our study is to investigate whether there is a relationship between sarcopenia and rotator cuff tears, and if so, to determine the location and type of the tear.",[123,124,125,126],"Rotator Cuff Tears","Sarcopenia","Shoulder Pain","Rotator Cuff Syndrome",[128,129,124],"Rotator cuff syndrome","Rotator cuff tear","2025-11-19",{"date":132,"type":32},"2025-11-26",{"date":134,"type":32},"2025-01-01",{"date":136,"type":21},"2025-12-30",{"name":38,"class":39},""]